RxDoctor Payments Data

Paul Hruby, MD

Retina Specialist · Little Rock, ARNPI 1174729016

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 25.3% of the total.

$1,448in general payments, 2019–2025

Across 60 payments — averaging $24.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$367
  • Regeneron Healthcare Solutions, Inc.$283
  • Astellas Pharma US Inc$123
  • Mallinckrodt Hospital Products Inc.$116
  • Genentech USA, Inc.$107
  • Optos, Inc.$100
  • plus $352 from 8 others

What the payments were for

  • Food & beverage$1,41998%
  • Other$282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few retina specialist providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$3,798,427
Medicare patients
899
Services billed
38,508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium16$5,609
Prednisolone Acetate127$5,089
Difluprednate15$1,995
Brimonidine Tartrate32$1,946
Ketorolac Tromethamine56$1,547
Atropine Sulfate42$1,412
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha78$887
Dorzolamide Hcl40$623
Timolol Maleate92$494
Ofloxacin16$183
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$176
Latanoprost24$175
ErythromycinErythromycin Base11$105
Ondansetron Hcl18$78
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$69

Paid to pharmacies, not to this prescriber.

Other retina specialist in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →